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that the launch of the NHI system. To improve the system even further, future chal-
lenge will be our motive to reform and also lead us to a new stage in health care.
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Glioblastoma (GBM) is an aggressive, high-grade glioma characterized by rapid 
growth and microvascular proliferation. Tumors are typically localized to the cer-
ebrum and rarely distantly metastasize. Worsening of neurocognitive symptoms is 
observed with GBM progression, and can significantly impact patient function and 
quality of life. Current treatments are non-curative and have not demonstrated 
an increase in overall survival. Progression-free survival (PFS) is a common pri-
mary endpoint in clinical trials of GBM therapies; however, it is important in this 
patient population to quantify how time without disease progression benefits 
patients. Recent decisions by health authorities and payers suggest an increasing 
trend towards the need for evidence of patient-centered endpoints, particularly for 
reimbursement decision-making. Assessment of neurocognitive deterioration due 
to GBM progression during the clinical trial period is challenging given the need to 
sensitively assess a range of symptoms that may manifest due to lesions in differ-
ent regions of the brain. A disease model, or conceptual framework, is needed to 
ground decision-making around choice of instruments, endpoints, and schedules 
of symptom assessments, thus ensuring measurement of the most patient and bio-
logically relevant symptoms. The framework presented here outlines the biological 
processes that contribute to non-focal symptoms of GBM, such as headache, as well 
as focal symptoms, such as visual disturbances, changes in memory, or loss of verbal 
expression. Considerations and challenges in assessing neurocognitive symptoms in 
GBM patients utilizing existing tools and methodologies are reviewed and identified.
PHP134
evidenCe Based aPProaCH to evaluate and imProve aCCess to 
mediCines in emerging markets
Shankar R.1, Hickson S.1, Sabat A.2
1IMS Consulting Group, Cambridge, UK, 2IMS Consulting Group, Mumbai, India
Developed countries have largely achieved universal health care coverage, while 
many developing countries are implementing steps to increase health care cover-
age. While the objective is the same, the health care systems and policies across 
countries differ across countries leading to different levels of access to medicines. 
To understand which systems and policies can lead to better access, we need a 
measure to evaluate how well countries do in terms of providing access to medi-
cine for their populations. In this paper, we develop a Country Access to Medicines 
Index that compares and ranks countries on access to medicine outcomes. This 
index is based on five pillars – ease of accessibility to health care workers and 
facilities, awareness of disease diagnosis and treatment, availability of medicines, 
affordability of medicines and adherence to right treatment. We identify key vari-
ables in each of these pillars and compare and rank 30 countries with more than 
60% of the world’s population on each of these variables, at an aggregate level 
on each pillar, and overall. We draw upon IMS data as well as international and 
country level sources to obtain the data needed for the measures. We then look at 
the health systems and policies in these countries to identify features that lead to 
better performance on the index. We find that five broad factors can help explain 
access to medicines performance. First is the level of financing of health care, espe-
cially reimbursement coverage. Second is a structured and transparent pricing and 
patient access system that prioritises resource allocation to high need diseases and 
patients and sets economically justifiable prices. Third is the level of development 
of health care infrastructure. Fourth, is the provider and pharmacy incentives that 
promote appropriate use of medicine. And finally, a system that ensures the proper 
implementation of health policy initiatives.
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The increasing adoption of Internet and social media have facilitated the emergence 
of patient opinion leaders (POLs). These influential individuals are living with a 
chronic disease and are writing about their experiences on Internet blogs and social 
media websites. Popular and highly-trusted patients are labeled as POLs because 
their work influences the decision-making of other patients. Top POLs have tens 
of thousands of followers who subscribe to their websites, blogs, and online social 
media accounts. POLs usually focus on one therapeutic area and provide disease-
related information, treatment options, and emotional support to other patients. 
Additionally, some POLs are health activists who help shape health policy and 
provide input into clinical trial design including endpoint development. As health 
care increases its focus to center around the individual patient, pharmaceutical 
companies and government agencies will seek out POLs for their personal perspec-
tives. A formal methodology to measure the influence and reach of POLs has yet 
to be established. Their influence on the Internet can be determined by the size of 
their audience (e.g., Twitter followers), relevancy of posted content to the disease 
state of interest, frequency of posted content, and perceived trustworthiness based 
on various scales (e.g., Google’s PageRank algorithm). By characterizing and index-
ing POLs, interested stakeholders can easily engage with them to incorporate the 
patient’s voice into clinical trials, market research, health policy, and marketing. As 
an example, researchers can capture and leverage the large audience of an influen-
tial POL to recruit patients for a clinical trial or to garner feedback on the endpoints 
of a clinical trial from the patients’ perspectives. This paper’s objective is to evaluate 
teria decision analysis. ConClusions: These and other methods may be used by 
CONITEC’s assessment, approaching the issues of efficiency and equity in decision 
making. Thus, is expected to contribute to the development and application of these 
decision-support tools and to improve the criteria of Ministry of Health for deciding 
which technologies to fund.
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objeCtives: An application of predictive and pharmacogenetic tests in appoint-
ment of targeted anti-cancer therapy and predict response to treatment. Considering 
significant practical necessity of molecular-genetic methods for health care and 
high cost, it is important to evaluate these technologies in terms of health econom-
ics. Methods: A systematic review of articles has been conducted using databases 
PubMed, The Cochrane Library, and published reports and market reviews. Results: 
In the period from 2007 to 2012 it is estimated the world market in vitro diagnostic 
(IVD) is increasing due to the development of molecular diagnostic tests and rapid 
test kits. Experts point out that a key factor in the growth segment of molecu-
lar diagnostics in recent years has been precisely the emergence of new oncology 
tests to prescribe targeted therapy. At the moment, in IVD diagnostics segment in 
Russia market is forecasted growth rate for 2014 at 10-20%. Price of tests for oncol-
ogy biomarkers depends on the technology: - for most routine immunological and 
chemical tests is between 10 and 15 USD; - for molecular genetic tests costs varies 
from 40 to 4000 USD per procedure. In addition to practiced in Russian Federation 
KRAS- and EGFR-testing, in this review discussed the practical value of: testing 
EML4-ALK mutation for crizotinib in non-small lung cancer; BRAF V600E-testing 
for vemurafenib in melanoma; HER2/neu-testing for trastuzumab in breast cancer. 
Thus, the Russian segment of the cancer diagnostics market is the fast-growing 
market. However, the analysis of the literature showed that until that time in the 
Russian Federation was not conducted clinical and economic evaluation of these 
medical technologies. ConClusions: The analysis revealed that evaluation of diag-
nostic test systems in oncology from the point of view of health economics of the 
Russian Federation is a topical field for research and requires a rigorous analysis.
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Transitional care management programs have been shown to improve medication 
adherence, elevate patient comprehension of their disease state, increase patient 
satisfaction, and reduce preventable readmission rates due to certain diagno-
ses (e.g., congestive heart failure). However, the true value of such programs has 
recently become more important to key health care decision makers as the United 
States transitions away from a fee for service model to a value based payment 
system. The provision of medication therapy management is a vital component 
of many transitional care management programs, yet the cost effectiveness of 
pharmacist interventions remains difficult to quantify. The inability to assign 
a universally accepted economic value to such transitional care programs has 
hindered the implementation of a sustainable business model for such services; 
despite the positive impact on patient health outcomes. This paper explores the 
unique challenges a national post-acute health care network faced while attempt-
ing to incorporate cost-effective clinical pharmacy services into its transitional 
care management programs. First, we discuss the impact of various strategies to 
stratify patient readmission risk in different settings of care. Second, the challenge 
to participate in a risk-sharing model in a health system still driven by patient 
choice is investigated. Finally, we evaluate the published methods used to quantify 
the economic impact clinical pharmacist interventions. Our assessment of the 
above topics is applied to three case studies; each located in a distinct region of 
the United States and with unique approaches to the provision and reimburse-
ment of health care. Our conclusions support the need for additional investment 
into the value of transitional care pharmacy services throughout the post-acute 
care continuum.
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The National Health Insurance (NHI) Program in Taiwan is a mandatory govern-
ment-run social insurance system cover 99% of the population. Since its inception 
in 1995, NHI has been facing the challenges of rapid increase on health care costs, 
particularly in 1998; nominal growth rate of NHI costs reached 11.4% per year. So 
many strategies have been introduced in controlling costs and in improving qual-
ity of care, and the Second-Generation NHI was implemented in January 1, 2013. 
Among them the pharmaceutical benefits and expenditures strategies were the 
most important reforms. The drug cost of NHI was about 4.4 billion USD in 2012, 
nearly 25% of total health insurance expenditure, and drug cost per capita was 204 
USD. Over 18,000 drugs were listed in the Drug Price List, and average new drugs 
listed time was 144 days. The average growth rate on drug fees was 4.8% for recent 10 
years. Many strategies had been introduced to control drug costs, such that : (1) Drug 
Price List was revised continuously based on setting reference prices for the drugs 
with same ingredients .The price was adjusted 9 times from 2000 to 2011. (2) “Drug 
Expenditure Target” policy into practice in January 1, 2013. It control unreasonable 
drug fees rising, and make drug policy predictable to the pharmaceutical industrial 
in Taiwan. (3) other reform such as focused on efficient pharmaceutical benefits 
and payment systems, equity in pharmaceutical transactions, public participation 
and information transparency. However, these biggest reform are now high hopes 
